Zoonotic vaccines form an essential frontier in infectious disease prevention, bridging the gap between human and animal health. Zoonotic diseases, caused ...

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

French drug company Sanofi announced it's discontinuing research and development for its next-generation mRNA flu vaccine.

Despite Sanofi CEO Paul Hudson’s confidence in vaccines, the French pharma has cut at least one mRNA flu shot program.

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to vaccines.

The global vaccine Contract Development and Manufacturing Organization (CDMO) market is projected to expand at a compound ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while holding the potential to provide up to $500 million more in development and ...

ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Our mission is to help overcome challenges with innovative tools and solutions from discovery to the ...

Health and Human Services Secretary Robert F. Kennedy Jr. is targeting the government’s Vaccine Injury Compensation Program, without which manufacturers might cease producing shots. (Eric ...